| Literature DB >> 28617860 |
Constantine Bloch-Infanger1,2, Veronika Bättig1, Jürg Kremo3, Andreas F Widmer1, Adrian Egli4, Roland Bingisser5, Manuel Battegay1, Stefan Erb1.
Abstract
OBJECTIVE: The increasing number of refugees seeking asylum in Europe in recent years poses new challenges for the healthcare systems in the destination countries. The goal of the study was to describe the evolution of medical problems of asylum seekers at a tertiary care centre in Switzerland.Entities:
Mesh:
Year: 2017 PMID: 28617860 PMCID: PMC5472310 DOI: 10.1371/journal.pone.0179537
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Monthly number of asylum seekers referred to the University Hospital Basel stratified for region of origin.
(A) time period 2004/05 (B) time period 2014/15. AFR: African Region; AMR: Region of the Americas; EMR: Eastern Mediterranean Region; EUR: European Region; SEAR: South-East Asia Region; WPR: Western Pacific Region; unknown: no data about the region of origin available. The bars represent the number of asylum seekers presenting at the University Hospital Basel per month and stratified into region of origin. Corresponding y-axis on the left of the diagram (n = 0–35 and 0–90, respectively). Black dotted line represents the monthly number of all asylum seekers entering Switzerland and applying asylum at any of the 5 national reception and procedure centres. Corresponding y-axis on the right of the diagram (n = 0–1200 and 0–4000, respectively).
Patient characteristics of all referred and hospitalized patients at the University Hospital Basel during the two study periods 2004/05 and 2014/15.
| 2004/05 | 2014/15 | p-value | |||||||
|---|---|---|---|---|---|---|---|---|---|
| All patients | Hospitalized patients | All patients | Hospitalized patients | ||||||
| Male | 137 | 70.3% | 31 | 68.9% | 298 | 57.8% | 53 | 65.4% | 0.003 |
| Female | 58 | 29.7% | 14 | 31.1% | 218 | 42.2% | 28 | 34.6% | |
| Age in years | 26.9 | 22.9–36.9 | 26.8 | 20.6–35.5 | 26.2 | 20.7–35.5 | 26.5 | 20.9–35.8 | 0.34 |
| EUR | 66 | 33.8% | 25 | 55.6% | 60 | 11.6% | 13 | 16.0% | <0.0001 |
| EMR | 25 | 12.8% | 7 | 15.6% | 78 | 15.1% | 12 | 14.8% | 0.439 |
| SEAR | 3 | 1.5% | 0 | 0.0% | 22 | 4.3% | 4 | 4.9% | 0.078 |
| WPR | 4 | 2.1% | 2 | 4.4% | 7 | 1.4% | 3 | 3.7% | 0.736 |
| AFR | 8 | 4.1% | 2 | 4.4% | 169 | 32.8% | 44 | 54.3% | <0.0001 |
| AMR | 0 | 0.0% | 0 | 0.0% | 8 | 1.6% | 3 | 3.7% | |
| Unknown | 89 | 45.6% | 9 | 20.0% | 172 | 33.3% | 2 | 2.5% | 0.003 |
| Infectious disease | 44 | 22.6% | 15 | 33.3% | 189 | 36.6% | 45 | 55.6% | <0.001 |
| Non-infectious disease | 151 | 77.4% | 30 | 66.7% | 327 | 63.4% | 36 | 44.4% | |
| Infectious diseases | 15 | 33.3% | 45 | 55.6% | 0.02 | ||||
| Internal medicine | 5 | 11.1% | 15 | 18.5% | 0.23 | ||||
| Gynaecology and obstetrics | 11 | 24.4% | 7 | 8.6% | 0.02 | ||||
| Neurology | 2 | 4.4% | 7 | 8.6% | 0.49 | ||||
| Surgery | 7 | 15.6% | 3 | 3.7% | 0.03 | ||||
| Psychiatrics | 4 | 8.9% | 2 | 2.5% | 0.19 | ||||
| Oncology | 1 | 2.2% | 2 | 2.5% | 1.00 | ||||
| All hospitalized patients | 6 | 5–11 | 5 | 4–10 | 0.28 | ||||
| Patients with infectious diseases | 7 | 5–20 | 7 | 4–10 | 0.41 | ||||
| Patients with non- infectious diseases | 6 | 4–9 | 4.5 | 2–6 | 0.14 | ||||
| Patients isolated | 13 | 28.9% | 24 | 29.6% | 0.920 | ||||
| Duration of isolation in days | 9.5 | 5–21 | 6 | 3–10 | 0.21 | ||||
AFR: African Region; AMR: Region of the Americas; EMR: Eastern Mediterranean Region; EUR: European Region; SEAR: South-East Asia Region; WPR: Western Pacific Region; IQR: interquartile range
* p-values refer to comparisons of variables from all patients between the two study periods
Fig 2Comparison of all hospitalized patients (n = 126) and hospitalized patients with infections (n = 60) between both study periods stratified by region of origin.
AFR: African Region; AMR: Region of the Americas; EMR: Eastern Mediterranean Region; EUR: European Region; SEAR: South-East Asia Region; WPR: Western Pacific Region.
Diagnosis of all hospitalized patients with infectious diseases and their region of origin during the two study periods.
| Diagnoses | n | % of all hospitalized patients | % of hospita-lized patients with infection | Regions of origin |
|---|---|---|---|---|
| n = 15 | ||||
| Tuberculosis | 4 | 8.9% | 50.0% | EMR (n = 1), EUR (n = 2), unknown (n = 1) |
| Bacterial skin infection | 2 | 4.4% | 25.0% | EMR (n = 1), unknown (n = 1) |
| Atypical pulmonary mycobacteriosis | 1 | 2.2% | 12.5% | EUR (n = 1) |
| Viral pulmonary infection | 1 | 2.2% | 12.5% | unknown (n = 1) |
| Exclusion of tuberculosis | 7 | 15.6% | - | EMR (n = 1), EUR (n = 5), WPR (n = 1) |
| n = 45 | ||||
| Malaria (8 M. vivax, 1 M. falciparum) | 9 | 11.1% | 20.4% | AFR (n = 9) |
| Bacterial pulmonary infection | 6 | 7.4% | 13.6% | AFR (n = 4), EMR (n = 1), EUR (n = 1) |
| Chickenpox | 5 | 6.2% | 11.4% | AFR (n = 4), EMR (n = 1) |
| Viral infection not otherwise specified | 5 | 6.2% | 11.4% | AFR (n = 5) |
| Bacterial skin- and soft tissue infection | 5 | 6.2% | 11.4% | AFR (n = 5) |
| ENT infection | 4 | 4.9% | 9.1% | AFR (n = 2), EUR (n = 1), SEAR (n = 1) |
| Influenza | 3 | 3.7% | 6.9% | AFR (n = 1), EUR (n = 1), SEAR (n = 1) |
| Active tuberculosis | 2 | 2.5% | 4.5% | WPR (n = 2) |
| Louseborne relapsing fever | 2 | 2.5% | 4.5% | AFR (n = 2) |
| Septic arthritis | 1 | 1.3% | 2.3% | EUR (n = 1) |
| Meningococcal meningitis | 1 | 1.3% | 2.3% | SEAR (n = 1) |
| Fungal pulmonary infection | 1 | 1.3% | 2.3% | AFR (n = 1) |
| Exclusion of tuberculosis | 1 | 1.3% | - | WPR (n = 1) |
AFR: African Region; AMR: Region of the Americas; EMR: Eastern Mediterranean Region; EUR: European Region; SEAR: South-East Asia Region; WPR: Western Pacific Region; ENT: ear nose throat infection
* number of hospitalized patients with infection;
$ 45 patients hospitalized in 2004/05 and 81 patients hospitalized in 2014/15
Reasons for isolation precautions of hospitalized asylum seekers during the two study periods.
| n | % of hospitalized patients | % of isolated patients | |
|---|---|---|---|
| n = 13 | 28.9% | 100.0% | |
| Suspected active tuberculosis (until exclusion of tuberculosis) | 8 | 17.8% | 61.5% |
| Confirmed tuberculosis | 4 | 8.9% | 30.8% |
| MRSA colonisation | 1 | 2.2% | 7.7% |
| n = 24 | 29.6% | 100.0% | |
| Suspected active tuberculosis (until exclusion of tuberculosis) | 9 | 11.1% | 37.5% |
| Scabies | 7 | 8.6% | 29.2% |
| Chickenpox (primary varicella virus infection) | 5 | 6.2% | 20.8% |
| MRSA colonisation | 4 | 4.9% | 16.7% |
| Influenza | 3 | 3.7% | 12.5% |
| Cutaneous diphtheria | 3 | 3.7% | 12.5% |
| Confirmed tuberculosis | 2 | 2.5% | 8.3% |
| Meningococcal meningitis | 1 | 1.2% | 4.2% |
MRSA: Methicillin-resistant Staphylococcus aureus
* number of hospitalized patients with infection;
$ 45 patients hospitalized in 2004/05 and 81 patients hospitalized in 2014/15